Eli Lilly is experiencing growing demand for their chronic weight management drug Zepbound, but struggles with manufacturing costs and competition from compounded versions. To reach more patients and compete, Lilly is offering Zepbound directly to patients at a discounted price through their digital health platform LillyDirect. The company’s top revenue generator, tirzepatide, is driving sales of both Zepbound and the diabetes medication Mounjaro. The move to direct-to-consumer sales aims to bypass pharmacy benefit managers and ensure authentic medication for obesity treatment. Other companies, like Pfizer, are following suit with direct sales strategies, potentially signaling a shift in the pharmaceutical industry.
Source link
With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs
